Human immunoglobulin(Chengdu Rongsheng Pharmaceutical Co., Ltd.)

Pharmacokinetic study 1. Main purpose To establish the population pharmacokinetic (popPK) model of IVIG and SCIG through pharmacokinetic study, obtain the kinetic characteristics of the drugs, and the dose adjustment factor (DAF) of IVIG and SCIG. 2. Secondary purpose To analyze the trough concentration level of total IgG of IVIG and SCIG during the trial. Clinical efficacy phase study 1. Main purpose To evaluate the effectiveness of subcutaneous human immunoglobulin (injection) produced by Chengdu Rongsheng Pharmaceutical Co., Ltd. in the treatment of primary immunodeficiency disease (PID). 2. Secondary purpose 1) To further observe and evaluate the clinical efficacy of SCIG using clinical secondary efficacy indicators. 2) To observe and evaluate the safety of SCIG during the trial.

Primary objective: To evaluate the effectiveness of intravenous human immunoglobulin (pH 4, 10%) (chromatographic method) in the treatment of patients with primary immune thrombocytopenia (ITP). Secondary objective: To evaluate the safety of intravenous human immunoglobulin (pH 4, 10%) (chromatographic method) in the treatment of patients with primary immune thrombocytopenia (ITP).